EA202092189A1 - Фармацевтический комбинированный препарат, содержащий эзетимиб и розувастатин - Google Patents

Фармацевтический комбинированный препарат, содержащий эзетимиб и розувастатин

Info

Publication number
EA202092189A1
EA202092189A1 EA202092189A EA202092189A EA202092189A1 EA 202092189 A1 EA202092189 A1 EA 202092189A1 EA 202092189 A EA202092189 A EA 202092189A EA 202092189 A EA202092189 A EA 202092189A EA 202092189 A1 EA202092189 A1 EA 202092189A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rosuvastatin
preparation containing
ezetimib
combined preparation
pharmaceutical combined
Prior art date
Application number
EA202092189A
Other languages
English (en)
Russian (ru)
Inventor
Хиук Дзун ЧО
Дзеонг Хиеон КИМ
Хо Таек Им
Йонг Ил Ким
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67986281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202092189(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of EA202092189A1 publication Critical patent/EA202092189A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
EA202092189A 2018-03-19 2019-03-11 Фармацевтический комбинированный препарат, содержащий эзетимиб и розувастатин EA202092189A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180031536A KR102569271B1 (ko) 2018-03-19 2018-03-19 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제
PCT/KR2019/002769 WO2019182276A1 (fr) 2018-03-19 2019-03-11 Préparation d'une association de produits pharmaceutiques comprenant de l'ézétimibe et de la rosuvastatine

Publications (1)

Publication Number Publication Date
EA202092189A1 true EA202092189A1 (ru) 2020-12-14

Family

ID=67986281

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092189A EA202092189A1 (ru) 2018-03-19 2019-03-11 Фармацевтический комбинированный препарат, содержащий эзетимиб и розувастатин

Country Status (10)

Country Link
KR (1) KR102569271B1 (fr)
CN (1) CN111886003A (fr)
CO (1) CO2020010204A2 (fr)
EA (1) EA202092189A1 (fr)
MX (1) MX2020009492A (fr)
PH (1) PH12020500656A1 (fr)
SG (1) SG11202007869WA (fr)
TW (1) TW201944992A (fr)
WO (1) WO2019182276A1 (fr)
ZA (1) ZA202004982B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102500643B1 (ko) * 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
WO2021226561A1 (fr) * 2020-05-07 2021-11-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Agents thérapeutiques contre la covid-19 et méthodes de traitement de la covid-19
BR112023003323A2 (pt) * 2020-08-25 2023-03-21 Daewoong Pharmaceutical Co Ltd Composição farmacêutica em forma de dosagem única
GB2622822A (en) * 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation
KR20250161310A (ko) 2024-05-08 2025-11-17 한미약품 주식회사 복약순응도가 개선된 에제티미브, 로수바스타틴 및 엠파글리플로진을 포함하는 복합제제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024889A2 (fr) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
ES2802252T3 (es) * 2012-05-01 2021-01-18 Althera Life Sciences Llc Formulación de comprimido oral que consiste en la combinación fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares
CN103585157B (zh) * 2013-11-13 2016-02-03 武汉武药科技有限公司 一种含依折麦布和瑞舒伐他汀的双层片及其制备方法
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
EP3243506A1 (fr) * 2016-05-09 2017-11-15 Adamed sp. z o.o. Composition pharmaceutique

Also Published As

Publication number Publication date
ZA202004982B (en) 2023-02-22
KR20190109892A (ko) 2019-09-27
MX2020009492A (es) 2021-01-15
KR102569271B1 (ko) 2023-08-23
CO2020010204A2 (es) 2020-08-31
TW201944992A (zh) 2019-12-01
PH12020500656A1 (en) 2021-06-21
WO2019182276A1 (fr) 2019-09-26
CN111886003A (zh) 2020-11-03
SG11202007869WA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
EA202092189A1 (ru) Фармацевтический комбинированный препарат, содержащий эзетимиб и розувастатин
EA202092580A1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
MX381787B (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos.
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
MX2020013853A (es) Compuestos innovadores.
MX389697B (es) Nuevos derivados de pirazolopirimidina.
MX375779B (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos.
EA201792047A1 (ru) Новые соединения
EA202090448A1 (ru) Дигидрооксадиазиноны
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
PH12019502365A1 (en) New bicyclic pyrazole derivatives
EA202091256A1 (ru) Новые антагонисты рецептора брадикинина
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
EP4327880A3 (fr) Forme à l'état solide de succinate de ribociclib
WO2017136731A8 (fr) Rapaglutines : nouveaux inhibiteurs de glut, et leur utilisation
EA201891608A1 (ru) Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
EA201891611A1 (ru) Роизводные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
HK1257296A1 (zh) 新的化合物及其用途
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
EA201891612A1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201990158A1 (ru) Производные бензодиоксана и их фармацевтическое применение
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
EA201992509A1 (ru) Гетероарилфениламинохинолины и аналоги
EA201990526A1 (ru) Конъюгат миноксидила и пептида